HCV/HIV coinfection among people who inject drugs and enter opioid substitution treatment in Greece: prevalence and correlates by Anastasios Fotiou et al.
Hepatology,                 
and Policy
MedicineFotiou et al. Hepatology, Medicine and Policy  (2016) 1:9 
DOI 10.1186/s41124-016-0017-5RESEARCH Open AccessHCV/HIV coinfection among people who
inject drugs and enter opioid substitution
treatment in Greece: prevalence and
correlates
Anastasios Fotiou1* , Eleftheria Kanavou1, Argyro Antaraki1, Clive Richardson2, Manina Terzidou1, Anna Kokkevi3
and Drug Related Infectious Diseases (DRID) Medical Doctors Group of OKANA4Abstract
Background: HCV/HIV coinfection in people who inject drugs is a public health issue, which presents a variety of
challenges to healthcare providers. The determinants of HCV/HIV coinfection in this population are nonetheless not
well known. The aim of the present study is to identify the factors associated with HCV/HIV coinfection in people
who inject drugs and enter drug-related treatment.
Methods: Linked serological and behavioral data were collected from people who entered 38 opioid substitution
treatment clinics in central and southern Greece between January and December 2013. Three mutually exclusive
groups were defined based on the presence of HCV and HIV antibodies. Group 1 clients had neither infection, Group 2
had HCV but not HIV, and Group 3 had HCV/HIV coinfection. Multinomial logistic regression analyses identified
differences between groups according to socio-demographic, drug use and higher-risk behavioral characteristics.
Results: Our study population consisted of 580 people who injected drugs in the past 12 months (79.8 % males,
with median age 36 years).79.4 % were HCV and 15.7 % HIV infected. Of those with complete serological data in
both HCV and HIV indicators, 20.4 % were uninfected, 64.0 % HCV monoinfected, and 14.9 % HCV/HIV coinfected.
HCV infection with or without HIV coinfection was positively associated with living alone or with a spouse/partner
without children, prior incarceration, drug injecting histories of ≥10 years, and syringe sharing in the past 12 months,
and negatively associated with never having previously been tested for HCV. HCV/HIV coinfection, but not HCV
infection alone, was positively associated with residence in urban areas (relative risk ratio [RRR] = 4.8, 95 % confidence
interval [CI]: 1.7–13.7, p = 0.004) and averaging >3 injections a day in the past 30 days (RRR = 4.5, 95 % CI: 1.6–12.8,
p = 0.005), and negatively associated with using a condom in the last sexual intercourse.
Conclusions: People who inject drugs and live in urban areas and inject frequently have higher risk of coinfection.
Findings highlight the need for scaling-up needle and syringe programs in inner city areas and promoting access of
this population to screening and treatment, especially in prisons. The protective role of living with parents and children
could inform the implementation of indicated interventions.
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Intravenous drug use is responsible for the majority of
new HCV infections and HCV is the most prevalent
viral infection among people who inject drugs [1–3]. It
is estimated that about 44 % of current injection drug
users in the countries of the European Union (EU) and
the European Free Trade Association (EFTA) have HCV
RNA [4]. HIV often co-occurs with HCV as both are
transmitted through infected blood, mainly through in-
jection drug use [1, 2, 5–7]. Chronic HCV infection is
the most common comorbidity in HIV infected drug
users, with the prevalence of HCV infection among HIV
infected drug users reaching rates higher than 70 % in
several countries and regions in western [1, 8] and east-
ern Europe [1], Latin America and the Caribbean [1],
and Asia [1, 7, 8].
HCV/HIV coinfection in drug users is a growing
public health concern. While HCV infection in itself
causes substantial morbidity and mortality [9–11], pa-
tients with HIV co-infection have much higher odds to
accelerate HCV infection to endstage liver disease
than those infected with hepatitis C alone [8, 12–14].
Coinfection with HIV also contributes to development
or acceleration of cardiovascular disease, neurocogni-
tive impairment, insulin resistance, and renal insuffi-
ciency [15].
HCV/HIV coinfection presents a variety of challenges
to healthcare providers [16–19]. HIV/HCV coinfected
drug users have significantly higher risk of having poorer
physical and mental health and use more healthcare ser-
vices compared to those infected with HIV only [20, 21].
Co-occurring HCV decreases the benefits of antiretro-
viral therapy (ART) [10], while drug addiction compli-
cates treatment regimens and leads to treatment-related
adverse events [22]. HIV/HCV coinfected people with
long injection histories are significantly less likely to
achieve virologic suppression and CD4 cell count recov-
ery, and have a higher risk of death [16, 23]. Finally,
coinfected drug users do not have equitable and univer-
sal access to HIV/AIDS and HCV treatment [16, 24, 25].
Barriers to treatment may be aggravated by the stigma
associated with drug users with comorbidities, and pre-
conceptions shared among healthcare providers who as-
sume low compliance, high risk of reinfection, and poor
response to ART [26, 27].Given the evidence suggesting higher morbidity and
mortality among coinfected drug users, there is a need
to document the prevalence of coinfection in this popu-
lation and to identify factors that put HCV uninfected
or HCV monoinfected populations at risk for HIV infec-
tion. The rather limited evidence available points to the
independent role of various behavioral and socio-
demographic factors. Behavioral factors include: longer
periods of injection drug use [5, 28–33]; receptive
sharing of injection equipment [5, 32–36]; frequent
injection [5, 31–33, 35]; present or past incarceration
[29, 35, 37, 38]; drug use during incarceration [39]; and
high risk sexual behavior [30]. Socio-demographic fac-
tors include: residence in metropolitan areas where in-
jection drug use takes place [5]; female gender [5];
older age [5, 39]; ethnicity (in northern American stud-
ies, e.g., Hispanic in [29] and Canadian aboriginal in
[5]); and lower education [28].
In Greece an estimated 2.0–2.6 people per 1000 people
aged 15–64 years are heroin drug users [40, 41]. Prob-
lems with heroin or other opioids are reported by the
majority (69 %) of people entering treatment [41]. In
2014, the estimated prevalence of antibodies to HCV
among injection drugs users entering all types of drug-
related treatment was 71 % overall, and 80 % among
first-ever treatment entries [41]. Until 2011, HIV among
injection drug users never exceeded 3 % of new HIV
diagnoses reported annually [41–43]. In 2011, the num-
ber of new HIV diagnoses increased sharply, rising from
5.5 in 2010 to 10.7 per 100,000 in 2012 [44, 45]. These
increases were observed only in Athens and were driven
by injecting drug use [42, 44, 45]. Studies conducted in
community samples of injection drug users in Athens
suggested an HIV prevalence of up to about 15 % [46].
In Greece, little is known about the profiles of injec-
tion drugs users characterized by different infection sta-
tuses for HCV and HIV (e.g., [43, 47, 48]), while no
published study is known to the authors to have ex-
plored the factors associated with coinfection. The
present study attempts to fill this gap and aims at identi-
fying injection drug users in the country who are at the
greatest infection risk based on their sociodemographic,
drug use and higher-risk behavioral characteristics. More
specifically, drawing from existing knowledge, the study
aims to differentiate drug users at risk of HCV
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tion so that policy makers and health care and harm re-
duction practitioners working close to this population
could utilize findings to design appropriate prevention
programs and help drug users with differing needs.
Methods
Study population and process
The study population consisted of all heroin or other
opioid users who started treatment in outpatient opioid
substitution treatment (OST) clinics of the Greek
Organization Against Drugs (OKANA) in central and
southern Greece in the period between January 1 and
December 31, 2013 and had injected drugs in the
12 months preceding their entry (n = 580). Given the
study aims, the inclusion criteria were dictated solely by
the need to have data on a wide range of behavioral vari-
ables that could be used as explanatory variables and
therefore allow for more meaningful analyses. During
the data collection period (2013) only the OST out-
patient clinics located in southern and central Greece
had established a data collection system which included
a wide range of behavioral variables. The 38 clinics from
which the participants were recruited had similar organ-
isational structure and employed common treatment
protocols. They were located in the capital cities of 14
prefectures in 9 of the 13 administrative regions of the
country (Attika, Peloponnese, Crete, Epirus, Thessaly,
Western Greece, Central Greece, Ionian Islands, and the
Southern Aegean region; representing about 73 % of the
total population in Greece). OST clinics and participants
in the study formed about 70 % of the total OST out-
patient clinics in operation and 72 % of the past
12 month injection drug users who entered OST in the
country in 2013.
Serological and behavioral data, linked through an
anonymised identification code, were collected in the
clinics through a routine data collection system estab-
lished by the Greek REITOX Focal Point of the
European Monitoring Centre for Drugs and Drug Addic-
tion (EMCDDA) (henceforth, Focal Point) since the end
of the 1990s. Data collection was paper-based and in-
volved all drug users starting treatment in the clinics.
Upon entry, each person was tested for HCV and HIV
antibodies and interviewed by health practitioners work-
ing in the respective clinic. Interviews were guided by
the use of a standardised structured questionnaire. Sero-
logical testing was provided for by internal OST treat-
ment protocols. No client-level refusals were reported
(although there were questionnaires with incomplete
serological data, attributed to reasons other than refusing
to test or to report results). Completed questionnaires
were subsequently sent to the Focal Point, where they
were checked for incomplete data and inconsistencies.The questionnaires were scanned and entered in the elec-
tronic database. A second round of (electronic) checks for
data entry errors, excessive number of missing values, lo-
gical inconsistencies, and double-counting was conducted
by an in-house statistician. The collection and manage-
ment of the data at the Focal Point was approved by the
Hellenic Data Protection Authority (Decision number:
2186, 1/11/2001).
Measures
The outcome of interest was HCV and HIV infection
status as a proxy of infection risk. Data were based on
serological tests (blood samples). Antibodies to HCV, in-
dicating HCV exposure, were detected by enzyme-linked
immunosorbent assay (ELISA), with recombinant immu-
noblot assay (RIBA) or enzyme immunoassay (EIA) con-
firmation (in all cases, commercial kits were used).
Antibodies to HIV, documenting HIV infection, were de-
tected by ELISA, with Western Blot immunoassay for
HIV-1/2 confirmation. The presence of HCV antibodies
and documented HIV infection indicated HCV/HIV co-
infection, the main outcome variable of the study. All
prevalence estimates reported are antibody prevalences.
Explanatory variables used in the analyses are shown
in Table 1. These were based on self-reports and com-
prised socio-demographic, drug use, and higher-risk be-
havioral indicators recommended by the EMCDDA for
monitoring drug-related infectious diseases at the na-
tional level [49, 50] and are supported by the relevant lit-
erature (reviewed in the Introduction [5, 28–39]).
Statistical analysis
Complete serological and behavioral data were collected
for 545 treatment entrants (94.0 %). We were interested
in identifying injection drug users at the greatest infec-
tion risk from their socio-demographic, drug use and
higher-risk behavioral characteristics, as well as differen-
tiating those at risk of HCV monoinfection from those
at risk of HCV/HIV coinfection. Multinomial logistic re-
gression analyses were conducted to identify differences
between different levels of infection status according to
these characteristics. Three mutually exclusive groups of
injection drug users were defined based on the presence
of HCV and HIV antibodies. Group 1 clients had neither
infection (uninfected, n = 111), Group 2 had HCV but
not HIV (HCV monoinfected, n = 349), and Group 3
had HCV/HIV coinfection (n = 81). These groups
formed the three levels of infection status. A fourth
group – those with HIV but not HCV (HIV monoin-
fected) – consisted of only four persons and was ex-
cluded from the analyses. Also excluded were 35 cases
with missing serological data in either HCV (n = 17, of
whom 3 were HIV positive) or HIV (n = 18, of whom 17
were HCV positive) indicators.




(n = 111, 20.4 %)
HCV monoinfectedc
(n = 349, 64.0 %)
HCV/HIV coinfectedd
(n = 81, 14.9 %)
N (%)e N (%) N (%) N (%)
Male (vs. Female)f 463 (79.8) 95 (85.6) 272 (77.9) 67 (82.7)
Median age [Inter-quartile range] 36 [12] 35 [7] 36 [14] 33 [10]
Greek nationality (vs. Non-Greek nationality) 554 (95.5) 109 (98.2) 332 (95.1) 76 (93.8)
Lived in urban area in the last 5 years (vs. Semi-urban/rural
area in the last 5 years)
444 (79.6) 84 (77.1) 264 (78.8) 71 (91.0)
Living alone or with spouse/partner without children
(vs. Living with familyg)
182 (31.9) 23 (20.7) 120 (34.4) 30 (37.0)
Homeless ≥1 night in the past 12 months (vs. Never in the
past 12 months)
186 (32.6) 26 (23.4) 107 (31.2) 42 (53.2)
Did not graduate high school (12th grade) (vs. Graduated
high school)
360 (62.1) 61 (55.5) 215 (62.0) 59 (74.7)
Employed (vs. Unemployed/student/other and economically
inactiveh)
137 (23.7) 32 (28.8) 88 (25.4) 9 (11.1)
Incarcerated at least once in lifetime (vs. Never) 382 (66.7) 55 (50.5) 241 (69.3) 57 (72.2)
Use of primary substance≥ 4 days a week (vs. Less frequently) 466 (80.5) 93 (83.8) 272 (78.2) 71 (87.7)
Use of ≥3 substances of abusei (vs. <3 substances of abuse) 367 (63.3) 66 (59.5) 219 (62.8) 53 (65.4)
Median length of injection (years) [Inter-quartile range] 14 [12] 10 [11] 15 [12] 13 [12]
Mean times of injection per day in the past 30 days [Standard
deviation]
1.9 [3.3] 1.2 [2.0] 1.6 [3.0] 3.9 [5.4]
Non-sterile syringe in last injection (vs. Sterile syringe in last
injection)
45 (8.1) 5 (4.8) 25 (7.5) 10 (12.7)
Shared syringes in the past 12 months (vs. No syringe sharing
in the past 12 months)
137 (25.4) 16 (15.1) 75 (23.1) 33 (44.6)
Shared other injection equipment in the past 12 months
(vs. Never in the past 12 months)
237 (43.7) 42 (40.4) 131 (40.3) 44 (57.1)
Two or more sexual partners in the past 12 months
(vs. <2 partners)
211 (36.6) 42 (38.9) 120 (34.5) 35 (43.2)
Sex in exchange for money etc. in the past 12 months
(vs. Never in the past 12 months/non-active)
37 (6.5) 4 (3.7) 22 (6.4) 8 (10.1)
No condom use in the last intercourse (vs. Use of condom
use or non-active)
246 (43.5) 51 (47.7) 155 (45.2) 21 (26.6)
Ever entered treatment for drug-related problems before
(vs. Never before)
388 (67.7) 67 (62.6) 244 (69.9) 51 (63.8)
Never tested for HCV before (vs. Tested for HCV before) 182 (32.1) 56 (51.9) 109 (32.2) 10 (12.3)
Never tested for HIV before (vs. Tested for HIV before) 192 (30.7) 50 (45.9) 100 (29.2) 12 (14.8)
aOST entrants with both statuses known, excluding four with HIV monoinfection. bDiagnosed HCV negative and HIV negative. cDiagnosed HCV positive and HIV
negative. dDiagnosed HCV positive and HIV positive. eWhere applicable, Median [Interquartile means] or Mean [Standard deviation]. fGender was measured by the
following item: “What is your gender?” Response options included “male”, “female”, “other (transgender)”. No person responded “other” in the sample used in the
present analysis. gIncludes children and/or parents. hThe category “economically inactive” includes the long-term sick, unpaid carers and persons living on
pensions or benefits, but excludes students. iTobacco use was not measured. Possible abuse of alcohol or non-medical use of prescription drugs is included
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in univariate multinomial logistic regression analyses.
Variables with p < 0.05 and gender were included in the
multivariable model. The final regression model in-
cluded only the variables which were statistically signifi-
cant (p < 0.10) in the multivariable model and was fitted
to the data from 450 cases for which complete data were
available. Likelihood ratio tests were carried out for the
overall effect of an explanatory variable and Wald tests
for the coefficients of individual categories against thereference category. Analyses were conducted using IBM
SPSS Statistics for Windows, Version 22.0 (Armonk, NY:
IBM Corp. IBM Corp. Released 2013). Relative risk ra-
tios (RRR) and 95 % confidence intervals (CI) are
presented.
Results
Table 1 presents socio-demographic, behavioral and
serological characteristics of the sample. The vast major-
ity (95.5 %) were of Greek origin, males (79.8 %), with
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length of injection 14 years (quartiles: 8, 20).
HCV infection was detected in 447 (79.4 %) of 563 cli-
ents with reported HCV test results and HIV in 88 of
562 cases (15.7 %). The uninfected (Group 1) comprised
20.4 % of those with complete serological data in both
HCV and HIV indicators (n = 111), 64.0 % were HCV
monoinfected (n = 349, Group 2) and 14.9 % (n = 81)
were HCV/HIV coinfected (Group 3). Four people
(0.7 %) were HIV monoinfected. The vast majority
(95.3 %) of HIV infected people had HCV comorbidity.
The HIV/HCV prevalence ratio (i.e., relative prevalence
of HIV compared to HCV) was 19.8 %. The prevalence
of HIV in HCV positive and HCV negative clients was
18.8 and 3.5 %, respectively (p < 0.001).
Among the correlates tested individually for their rela-
tion to the infection groups (univariate analyses) a num-
ber of factors showed positive association (p < 0.05) with
infection status. These included: aged ≥35 years, living
in an urban area, living alone or with spouse / partner
without children, having been homeless in the past
12 months, having not been graduated from high-school,
not being employed, having been incarcerated, long in-
jection history, frequent daily injection, and having
shared injection equipment in the past 12 months. No
condom use in the last intercourse, never having been
tested for HCV, and never having been tested for HIV
showed negative association with infection status
(Table 2).
The results of the multivariate analysis (final model com-
prising only the significant - p < 0.10 - variables from the
previous model) are shown in Table 3. The probability of
belonging to an infected group versus the uninfected group
was positively related to living alone or with a spouse/part-
ner without children (p = 0.007, overall p-value for this co-
variate), incarceration (p = 0.018), having an injecting
history of at least 10 years (p = 0.002), and having shared sy-
ringes in the past 12 months (p = 0.002). The risk of infec-
tion was reduced in injection drug users who reported that
they had never previously been tested for HCV (p = 0.001).
Risk factors for HCV/HIV coinfection, but not HCV
monoinfection, were residence in major urban areas
(RRR = 4.8, 95 % CI: 1.7–13.7, p = 0.004) and aver-
aging > 3 injections a day in the last 30 days (RRR = 4.5,
CI: 1.6–12.8, p = 0.005). The risk of coinfection was
reduced in injection drug users who did not use a con-
dom in the last sexual intercourse (RRR = 0.4, CI: 0.2–
0.9, p = 0.018).
Additional multivariate analyses, with the HCV mono-
infected group as the reference category, showed that
the risk of HCV/HIV coinfection was higher among
those living in urban areas (RRR = 3.4, 95 % CI: 1.3–8.7,
p = 0.012), averaging >3 injections a day in the last 30 days
(RRR = 4.0, CI: 2.0–8.2, p < 0.001), and lower amonginjection drug users who were aged ≥35 years (RRR = 0.4,
CI: 0.2–0.7, p = 0.004), did not use a condom in the last
sexual intercourse (RRR = 0.5, CI: 0.3–0.9, p = 0.030), and
had never previously been tested for HCV (RRR = 0.4, CI:
0.2–0.8, p = 0.015) (data not shown in Table).
Discussion
Greece is a country with a high HIV and HCV epidemic
among people who inject drugs (41, 46). In the present
study we estimated the prevalence of HCV/HIV coinfec-
tion in a sample of injection drug users entering OST in
Greece in 2013 to be 14.9 %, with almost all HIV sero-
positive persons (95.3 %) having HCV comorbidity. We
also aimed to identify injection drug users at the greatest
risk of HCV/HIV coinfection on the basis of their socio-
demographic, drug use and higher-risk behavioral char-
acteristics. Our findings corroborate existing evidence
suggesting that lengthy injecting careers, syringe sharing
and prior incarceration independently increase the risk
of infection. The present study additionally showed that
the risk also increases in people who inject drugs and
live alone or with a spouse/partner without children (as
opposed to living with parents and /or children). Risk
factors for HCV/HIV coinfection, but not HCV monoin-
fection, were residence in major urban areas and aver-
aging more than 3 injections a day in the past 30 days.
Specifically, injection drug users with injecting histor-
ies of 10 or more years were at increased risk for both
HCV monoinfection and HCV-HIV coinfection (almost
six and fourteen times higher, respectively) compared to
drug users with shorter injecting histories. Similarly,
sharing a used syringe also increased the risk of infec-
tion, with those who reported syringe sharing in the
12 months preceding the treatment entry having almost
five times greater risk of coinfection compared to those
who had not shared in the past year. These findings are
supported by ample evidence implicating long injecting
histories and syringe sharing as key risk factors for coin-
fection [31–33, 35, 51]. There is also ample evidence
suggesting that interventions that offer OST and HCV
and HIV treatment to infected persons, coupled with
needle and syringe programs (NSPs) and safer injecting
rooms, may be vital in interrupting higher-risk injecting
routines and reducing syringe sharing, thereby prevent-
ing new infections and reducing prevalence in this popu-
lation (see [52] for review; also [53–60]). Harm
reduction programs in Greece have generally had limited
coverage [61, 62]. The 2011 HIV outbreak in injection
drug users, coupled with international pressure and EU
funding support, led to a public health response that fo-
cused on enforcement-based interventions covering
diagnosis, scaling-up NSPs and OST, and linkage of HIV
seropositives to ART (see e.g., [46]). Although restricted
to Athens, interventions coincided with a significant
Table 2 Results of univariate analysis of factors associated with HCV monoinfection and HCV/HIV coinfection
HCV monoinfecteda vs. Uninfectedc HCV/HIV coinfectedb vs. Uninfected









Male (vs. Female)g 0.164 0.6 0.3 1.1 0.083 0.8 0.4 1.8 0.589 541
Aged ≥35 years (vs. Aged <35 years) 0.015 1.4 0.9 2.2 0.114 0.7 0.4 1.3 0.265 541
Greek nationality (vs. Non-Greek nationality) 0.224 0.4 0.1 1.6 0.174 0.3 0.1 1.5 0.133 541
Lived in urban area in the past 5 years (vs. Lived in
semi-urban/rural area)
0.019 1.1 0.7 1.9 0.701 3.0 1.2 7.4 0.016 522
Living alone or with spouse/partner without children
(vs. With familyh)
0.012 2.0 1.2 3.3 0.007 2.3 1.2 4.3 0.013 541
Homeless ≥1 night in the past 12 months (vs. Never
in the past 12 months)
<0.001 1.5 0.9 2.4 0.119 3.7 2.0 6.9 <0.001 533
Did not graduate high school (12th grade)
(vs. Graduated high school)
0.022 1.3 0.8 2.0 0.225 2.4 1.3 4.5 0.007 536
Unemployed / student / other (vs. Employed) 0.013 1.2 0.7 2.0 0.425 3.0 1.3 6.8 0.009 539
Economically inactivei (vs. Employed) 1.1 0.5 2.2 0.859 4.3 1.6 11.7 0.005
Incarcerated at least once in lifetime (vs. Never) 0.001 2.2 1.4 3.4 <0.001 2.5 1.4 4.7 0.003 536
Use of primary substance≥ 4 days a week
(vs. <4 days a week)
0.086 0.7 0.4 1.2 0.203 1.4 0.6 3.2 0.454 540
Use of ≥3 substances of abuse (vs. Use of
<3 substances of abuse)j
0.690 1.1 0.7 1.8 0.534 1.3 0.7 2.3 0.400 541
2–4 years of injection (vs. 0–1 year) <0.001 1.6 0.5 4.8 0.404 8.8 1.0 78.1 0.051 535
5–9 years of injection (vs. 0–1 year) 2.8 1.0 7.7 0.040 7.8 0.9 66.6 0.060
≥10 years of injection (vs. 0–1 year) 6.1 2.4 15.1 <0.001 11.0 1.4 87.3 0.023
Injected on average 2–3 times per day in the past
30 days (vs. <2 times/day)
<0.001 0.7 0.3 1.7 0.472 2.2 0.8 6.1 0.128 529
Injected on average >3 times per day in the past
30 days (vs. <2 times/day)
1.1 0.5 2.4 0.824 5.0 2.1 11.7 <0.001
Non-sterile syringe in last injection (vs. Sterile syringe
in last injection)
0.149 1.6 0.6 4.3 0.342 2.9 0.9 8.9 0.062 519
Shared syringes in the past 12 months (vs. Never in
the past 12 months)
<0.001 1.7 0.9 3.1 0.080 4.5 2.2 9.1 <0.001 504
Shared other injection equipment in the past 12 months
(vs. Never in the past 12 months)
0.024 1.0 0.6 1.6 0.989 2.0 1.1 3.6 0.026 506
Two or more sexual partners in the past 12 months
(vs. <2 sexual partners)
0.300 0.8 0.5 1.3 0.404 1.2 0.7 2.1 0.550 537
Sex in exchange for money etc. in the past 12 months
(vs. Never in the past 12 months/non-active)
0.218 1.8 0.6 5.2 0.306 2.9 0.8 10.0 0.092 529
No condom use in last intercourse (vs. Use of condom
use or non-active)
0.005 0.9 0.6 1.4 0.654 0.4 0.2 0.7 0.004 529
Ever entered treatment for drug-related problems before
(vs. Never before)
0.275 1.4 0.9 2.2 0.157 1.0 0.6 1.9 0.874 536
Never tested for HCV before (vs. Tested for HCV before) <0.001 0.4 0.3 0.7 <0.001 0.1 0.1 0.3 <0.001 528
Never tested for HIV before (vs. Tested for HIV before) <0.001 0.5 0.3 0.8 0.001 0.2 0.1 0.4 <0.001 533
aDiagnosed HCV positive and HIV negative. bDiagnosed HCV positive and HIV positive. cDiagnosed HCV negative and HIV negative.dOverall p-value for this
covariate. eRRR: relative risk ratios. f95 % confidence intervals. gGender was measured by the following item: “What is your gender?” Response options included
“male”, “female”, “other (transgender)”. No person responded “other” in the sample used in the present analysis.hIncludes children and or parents. iThe category
“economically inactive” includes the long-term sick, unpaid carers and persons living on pensions or benefits, but excludes students. In the present analysis, the
status “student” was collapsed with the category “unemployed” under the assumption that, like people who are unemployed, students may be motivated to
improve their physical and socioeconomic conditions and therefore are ready to undertake fewer health risks. jTobacco use was not measured. Possible abuse of
alcohol or non-medical use of prescription drugs is included
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Table 3 Results of the multinomial logistic regression analysis of factors associated with HCV monoinfection and HCV/HIV
coinfection (final model comprising only the significant – p < 0.10 – variables from the previous model, n = 450)
Correlate (vs. Reference category) HCV monoinfecteda vs. Uninfectedc HCV/HIV coinfectedb vs.
Uninfected
pd RRRe 95 % CIf p RRR 95 % CI p
Lower limit Upper limit Lower limit Upper limit
Male (vs. Female)g 0.023 0.4 0.2 0.9 0.018 0.7 0.2 2.0 0.499
Aged ≥35 years (vs. Aged <35 years) 0.015 1.2 0.7 2.1 0.493 0.5 0.2 1.0 0.066
Lived in urban area in the last 5 years (vs. Lived in
semi-urban/rural area)
0.006 1.4 0.8 2.6 0.255 4.8 1.7 13.7 0.004
Living alone or with a spouse/partner without children
(vs. With familyh)
0.007 2.6 1.3 4.9 0.005 3.1 1.3 7.3 0.010
Incarcerated at least once in lifetime (vs. Never) 0.018 2.0 1.2 3.4 0.008 2.5 1.1 5.3 0.021
5–9 years of injection (vs. 0–1 year) 0.002 2.4 0.8 7.2 0.134 6.0 0.6 60.6 0.129
2–4 years of injection (vs. 0–1 year) 1.5 0.4 5.6 0.529 8.2 0.7 92.2 0.088
≥10 years of injection (vs. 0–1 year) 5.5 1.9 15.9 0.002 14.1 1.5 133.8 0.021
Injected on average 2–3 times per day in the past 30 days
(vs. <2 times/day)
0.003 1.1 0.3 3.4 0.916 2.6 0.6 10.5 0.186
Injected on average >3 times per day in the past 30 days
(vs. <2 times/day)
1.1 0.4 2.9 0.805 4.5 1.6 12.8 0.005
Shared syringes in the past 12 months (vs. No syringe
sharing in the past 12 months)
0.002 2.5 1.2 5.2 0.014 4.7 1.9 11.5 0.001
No condom use in last intercourse (vs. Use of condom
or non-active)
0.043 0.8 0.5 1.4 0.424 0.4 0.2 0.9 0.018
Never tested for HCV before (vs. Tested for HCV before) 0.001 0.6 0.3 0.9 0.028 0.2 0.1 0.5 <0.001
aDiagnosed HCV positive and HIV negative. bDiagnosed HCV positive and HIV positive. cDiagnosed HCV negative and HIV negative. dOverall p-value for this
covariate. eRRR: relative risk ratios. f95 % confidence intervals. gGender was measured by the following item: “What is your gender?” Response options included
“male”, “female”, “other (transgender)”. No person responded “other” in the sample used in the present analysis. hIncludes children and / or parents
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grams have not proved financially sustainable [64]. Fur-
thermore, under the austerity policies imposed from
2010 up to the present, public spending allotted to harm
reduction has been minimal.
Living alone or only with a spouse/partner (without
children or other family members, e.g., parents) trebled
in our study the risk of HCV infection with or without
HIV. Previous research has shown that higher-risk drug
use is positively associated with intimacy among friend-
ship networks [65]. At the same time, pockets of social
support may reduce HCV and HIV related morbidity
and mortality [66]. Taking care of children and living
with a member of one’s (biological) family is an often
overlooked yet potentially important aspect of social
support, especially in countries like Greece where the
family retains its pivotal role in the lives of drug users
[67]. The latter may influence health behaviors through
self-regulation in conformity to norms or through
others’ health promoting behaviors and expectations
[68]. In our study the likely absence of social support
may have nurtured the adoption of risky behaviors in re-
lation to HIV.
Our findings also suggest that those who have been in-
carcerated have twice as high a risk of HCV infectionwith or without HIV, suggesting that prison environ-
ments foster high-risk injection and sexual behavior and
hence the acquisition of infection. The cross-sectional
nature of our data does not allow us to make inferences
about causality, but the independent association between
incarceration and HCV, HIV, and HCV/HIV coinfection
in this population is well documented [51, 69]. In
Greece, no administrative alternatives to imprisonment
are implemented for drug users. As of 2016, prisoners in
Greece do not have access to sterile injection equipment
or condoms, while screening, HIV counseling, and ART
are not routinely available [70]. Since 2015, OST and
drug-related health care has been available in only two
of the eighteen prison units in operation in the country.
Furthermore, following incarceration, low coverage of
services and other structural barriers (e.g., lack of essen-
tial documents, language restrictions, poverty, stigma or
fear) may have promoted behaviors with higher health
risk in this population.
HCV/HIV coinfection (but not HCV monoinfection)
was independently associated with frequent injection
and residing in metropolitan areas. More specifically, liv-
ing in an urban area and averaging more than 3 injec-
tions a day increased the risk by almost five. Living in an
urban area represents a marker for high-risk factors.
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coupled with relatively easy access to multiple and novel
substances of unknown composition and adverse effects,
participation in larger, unknown and changing injection
and sexual networks, and exposure to sex work (e.g. [5]).
In addition, fear of arrest or punishment may displace or
lead drug injectors to avoid using outreach programs, or
to hurried injections and injection practices that increase
opportunities for parenteral exposures to HIV.
Theoretically, having a test for infectious diseases is an
indicator of health-protecting attitude [50], leading to the
assumption that drug users who have been tested in the
past will more likely be uninfected. Counterintuitively, our
study showed that the risk of being infected was negatively
associated with previous HCV testing. Unfortunately, the
cross-sectional nature of the present study and the fact
that we did not measure the time at which both the infec-
tion and previous testing occurred, or whether the test re-
sult was known to the participant, prevent us from being
able to interpret these findings.
There was also a negative association between having
used a condom in the last sexual intercourse and the
risk of HCV/HIV coinfection (but not of HCV monoin-
fection). Again, lack of additional data (e.g., frequency of
sexual activity, partner’s sexual orientation etc.) or more
relevant variables (e.g., overall consistency of condom
use) prevent us from fully explaining these findings.
However, a number of hypotheses may be proposed:
first, it may be that those who responded that they did
use a condom in their last sexual intercourse had been –
prior to the last occasion– largely reckless in their sexual
behavior. Second, the category included people who had
no sex in the last 12 months, who possibly knew their
positive serological status and abstained from sex. Third,
the present data were collected in a period in which the
HIV epidemic and the corresponding health-risk aware-
ness and HIV counselling programs were at their great-
est extent, reaching a substantial number of injection
drug users (especially in Athens) [41, 46, 62]. Against
this background it may be that those who reported that
they did use a condom in the last sexual intercourse
were giving the socially desired response. Finally, it may
also be that those who responded that they did not use a
condom in the last sexual intercourse were more cau-
tious with other high-risk behaviors.
The findings of our study should be seen in the light of
several limitations. First, the study participants were re-
cruited only from OST outpatient clinics and only from
central and southern Greece. In theory this affects the
generalizability of our findings. However, clinics and partici-
pants in the present study comprised about 70 % of na-
tional totals that year (2013). Second, we focused only on
injection drug users and injection practices in general
among heroin and other opioid users. Using stimulants(e.g., in the case of Greece, ‘shisha’, a variant of metham-
phetamine) also has destabilizing effects [5, 71]. However,
only a small proportion of study participants reported pri-
mary use of stimulants, including cocaine (2.4 %), and
therefore this behavior was not included as a correlate in
the analysis. Third, the cross-sectional design of the study
does not allow the establishment of a causal relationship or
a direction of causality between empirically related vari-
ables. Furthermore, as we did not measure whether HIV
and HCV seropositives were known positives prior to the
data collection, or whether they had already received spe-
cialised infectious diseases treatment, we could not check
for possible interactions with other variables examined in
the study. Finally, although data collection protocols have
been employed for years in ways that elicit valid responses,
possible misreporting associated with recall and social de-
sirability biases [72] during the interview cannot be
overlooked.Conclusions
The positive association observed between infection and
lengthy injection histories points to the need for scaling-
up OST programmes and retaining people in treatment.
The positive association between HCV/HIV coinfection
and, independently, frequent daily injection and living in
urban areas suggests that more injection equipment,
screening and brief advice are required in order to reach
out to more injection drug users, especially in the inner
city areas of all major cities in the country. Prior incar-
ceration increases the risk of infection, and this alone
highlights the need to provide routine testing and harm
reduction services in all detention centres in the coun-
try. Importantly, keeping in contact with their family
(i.e., parents and/or children) may reduce the risk of in-
fection for people who inject drugs, and this element
could guide counselling that takes place at the treatment
centre level and relies on building up family support
systems.
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